Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals announced the receipt of its one-third share of the net proceeds from the sale of a Rare Pediatric Disease Priority Review Voucher, which totaled $150 million. This voucher was awarded following the FDA approval of DAYBUE™ for Rett syndrome, with Neuren’s partner, Acadia Pharmaceuticals, managing the sale. The financial boost from this transaction potentially strengthens Neuren’s operations and supports its ongoing drug development efforts, enhancing its positioning within the pharmaceutical industry focused on rare neurological disorders.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals is a company focused on developing new drug therapies for serious neurological disorders that manifest in early childhood, often with limited or no approved treatment options. The company has received ‘orphan drug’ designation for its programs in the United States, which offers incentives for developing treatments for rare and serious diseases. Neuren has developed DAYBUE™ (trofinetide), approved for the treatment of Rett syndrome, and has another drug candidate, NNZ-2591, in development for neurodevelopmental disorders.
YTD Price Performance: 10.76%
Average Trading Volume: 1,200
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.12B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.
